Skip to main content

Table 2 Plasma phospholipids fatty acid levels after EPA + DHA and placebo supplementation in 12 men with type 2 diabetes

From: Eicosapentaenoic and docosahexaenoic acid supplementation and inflammatory gene expression in the duodenum of obese patients with type 2 diabetes

 

Placebo

EPA + DHA

Difference

P

 

Fatty acid levels (%)

LA

19.9 (3.6)

19.3 (2.9)

−0.6

0.09

ALA

0.21 (0.09)

0.19 (0.11)

−0.02

0.85

DGLA

3.82 (1.57)

2.87 (0.65)

−0.95

0.001

AA

9.40 (2.05)

7.97 (1.37)

−1.43

0.0005

EPA

1.00 (0.93)

3.53 (1.65)

2.53

0.0005

DPA

1.03 (0.34)

1.25 (0.26)

0.22

0.0005

DHA

2.96 (1.15)

4.43 (1.26)

1.47

0.0005

  1. Data are expressed as median and interquartile range in parentheses. P values were calculated using Wilcoxon matched-pairs signed-rank tests. Abbreviations: AA, arachidonic acid; ALA, alpha-linolenic acid; DGLA, dihomo-γ-linoleic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; LA, linoleic acid; PUFA, polyunsaturated fatty acids.